Multimodal therapy for colon cancer: State of the art;Kolonkarzinom: Aktueller Stand der multimodalen Therapie

Zentralblatt fur Chirurgie - Zeitschrift fur Allgemeine, Viszeral- und Gefasschirurgie

Volumn 136, Issue 4, 2011, Pages 325-333

  Weber, T ^a   Link, K H ^a  

^a Asklepios Paulinen Klinik   (Germany)

Author keywords

colon cancer; multimodal therapy; therapy

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; MONOCLONAL ANTIBODY; PLATINUM COMPLEX;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; AGED; ARTICLE; CANCER STAGING; COLON TUMOR; COOPERATION; DRUG DELIVERY SYSTEM; HUMAN; INTERDISCIPLINARY COMMUNICATION; LIVER TUMOR; LYMPH NODE METASTASIS; LYMPHADENECTOMY; METASTASIS; METASTASIS RESECTION; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PATIENT CARE; PROGNOSIS;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; COMBINED MODALITY THERAPY; COOPERATIVE BEHAVIOR; DRUG DELIVERY SYSTEMS; FLUOROURACIL; HUMANS; INTERDISCIPLINARY COMMUNICATION; LEUCOVORIN; LIVER NEOPLASMS; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; METASTASECTOMY; NEOADJUVANT THERAPY; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PATIENT CARE TEAM; PROGNOSIS;

EID: 80052166111     PISSN: 0044409X     EISSN: 14389592     Source Type: Journal    
DOI: 10.1055/s-0031-1271562     Document Type: Article

References (67)

1. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Kebsregister in Deutschland e.V. (Hrsg). Krebs in Deutschland 2005/2006. Häufigkeiten und Trends. 7. Ausgabe Berlin Westkreuz-Druckerei 2010 36-39 ISBN 978-3-89606-207-9
2. Link K H., Mörschel M, Sagban T A. et al. Chirurgie und multimodale Therapie des Kolonkarzinoms: Evidensbasis? Chir Gastroenterol 2004 20 39-54 (Pubitemid 38621581)
3. Link K H., Kornmann M, Staib L et al. Increase of survival benefit in advanced resectable colon cancer by extent of adjuvant treatment: results of a randomized trial comparing modulation of 5-FU+levamisole with folinic acid or with interferon-alpha. Ann Surg 2005 242 178-187 (Pubitemid 41033433)
4. Andre T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucoverin as adjuvant treatment in stageII or III colon cancer in the MOSAIC trial. J Clin Oncol 2009 27 3109-3116
5. Bokemeyer C, Bondarenko I, Hartmann J T. et al. KRAS status and efficacy of first-line treatment of patients with metastatic colorectal cancer (mCRC) with FOLFOX with or without cetuximab: The OPUS experience. J Clin Oncol 2008 26 78-178
6. Van Cutsem E, Lang I, Dhaens G et al. KRAS status and efficacy in the first line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. J Clin Oncol 2008 26 suppl 5
7. Kornmann M, Schwabe W, Sander S et al. Thymidylate Synthase and Dihydropyrimidine Dehydrogenase mRNA Expression Levels: Predictors for Survival in Colorectal Cancer Patients Receiving Adjuvant 5-Flurouracil. Clin Canc Res 2003 9 4116-4124 (Pubitemid 37204028)
8. Popat S, Hubner R, Houlston R S. Systemic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005 23 609-618 (Pubitemid 46224239)
9. Ribic C M., Sargent D J., Moore M J. et al. Tumor microsatellite- instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003 349 247-257 (Pubitemid 36859476)
10. Feifel G, Hildebrandt U. Neue Entwicklungen in der operativen Therapie des Kolonkarzinoms. Onkologe 1999 1 24-29 (Pubitemid 29161373)
11. Weber T, Link K H. Radikale Chirurgie bei primär metastasierten kolorektalen Karzinomen. Chir Gastroenterol 2007 23 360-366 (Pubitemid 351185617)
12. Fleshman J, Sargent D J., Green E et al. Laparoscopic colectomy for cancer is not inferior to open surgery based on 5-year data from the COST Study group trial. Ann Surg 2007 246 655-662 (Pubitemid 47480618)
13. Buunen M, Veldkamp R, Hop W C. et al. Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomized clinical trial. Lancet Oncol 2009 10 44-52
14. Lacy A M., Delgado S, Castellas A et al. The long term results of a randomized clinical trial of laparoscopy-assisted versus open surgery for colon cancer. Ann Surg 2008 248 1-7
15. Weber T, Link K H. Submukosakarzinome des Gastrointestinaltraktes Kolon: pro Chirurgie. Viszeralmedizin 2009 25 40-45
16. Link K H., Sagbahn T A., Mörschel M et al. Colon cancer: survival after curative surgery. Langenbecks Arch Surg 2005 390 83-93 (Pubitemid 40487431)
17. Chok K SH, Law W L. Prognostic factors affecting survival and recurrence of patients with pT1 and pT2 colorectal cancer. World J Surg 2007 31 1485
18. Greene F L., Stewart A K., Norton H J. A new TNM staging strategy for node positive (StageIII) colon cancer: an analysis of 50042patients. Ann Surg 2002 236 416-421
19. Deinlein P, Reulbach U, Stolte M et al. Risikofaktoren der lymphogenen Metastasierung von kolorektalen pT1 Karzinomen. Pathologe 2003 24 387-393 (Pubitemid 37173993)
20. Hassan C, Zullo A, Risio M et al. Histologic risk factors and clinical outcome in colorectal malignant polyp: a pooled analysis. Dis Colon Rectum 2005 48 1588-1596 (Pubitemid 41032084)
21. Schmiegel W, Reinacher-Schick A, Arnold D et al. S3-Leitline Kolorektales Karzinom Aktualisierung 2008. Z Gastroenterol 2008 46 799-840
22. Kikuchi R, Takano M, Takagi K et al. Management of early invasive colorectal cancer. Risk of recurrence and clinical guidelines. Dis Colon Rectum 1995 38 1286-1295
23. Yasuda K, Inomata M, Shiromizu A et al. Risk factors for occult lymph node metastasis of colorectal cancer invading the submucosa and indications for endoscopic mucosal resection. Dis Colon Rectum 2007 50 1370-1376 (Pubitemid 47472389)
24. Yamamoto S, Watanabe M, Hasegawa H et al. The risk of lymph node metastasis in T1 colorectal carcinoma. Hepatogastroenterology 2004 51 998-1000 (Pubitemid 38822457)
25. Suzuki T, Sadahiro S, Mukoyama S et al. Risk of lymph node and distant metastases in patients with early invasive colorectal cancer classified as Haggitts level4 invasion: image analysis of submucosal layer invasion. Dis Colon Rectum 2003 46 203-208 (Pubitemid 36222620)
26. Gill S, Loprinzi C L., Sargent D J. et al. Pooled analysis of fluorouracil based adjuvant therapy for stageII and III colon cancer: who benefits and by how much ? J Clin Oncol 2004 22 1797-1806 (Pubitemid 41095169)
27. Gray R, Barnwell J, McConkey C et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomized study. Lancet 2007 370 2020-2029
28. Morris M, Platell C, de Boer M et al. Population based study of prognostic factors in stageII colonic cancer. Br J Surg 2006 93 866-871 (Pubitemid 44035260)
29. Jestin P, Nilsson J, Heurgren M et al. Emergency surgery for colonic cancer in a defined population. Br J Surg 2005 92 94-100 (Pubitemid 40144201)
30. McArdle C S., McMillan D C., Hole D J. The impact of blood loss, obstruction and perforation on survival in patients undergoing curative resection for colon cancer. Br J Surg 2006 93 483-488
31. George S, Primrose J, Talbot R et al. Will Rogers revisted: prospective observational study of survival of 3592patients with colorectal cancer according to number of nodes examined by pathologists. Br J Cancer 2006 95 841-847 (Pubitemid 44498099)
32. Chen S l, Bilchik A J. More extensive nodal dissection improves survival for stagesI to III of colon cancer: a population-based study. Ann Surg 2006 244 602-610
33. OConnell M J., Mailliard J A., Kahn M J. et al. Controlled trial of fluorouracil and low-dose leucovorin given 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997 15 246-250 (Pubitemid 27020580)
34. Teixeira L, Hickish T, Tournigand C et al. Efficacy of FOLFOX4 as adjuvant therapy in stageII colon cancer: A new analysis of the mosaic trial according to risk factors. J Clin Oncol 2010 28 3524
35. Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil and leucovorin as adjuvant treatment for colon cancer. New Engl J Med 2004 350 2343-2351 (Pubitemid 38702845)
36. Kuebler J P., Wieand H S., OConnell M J. et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stageII and III colon cancer: results from NSABP C-07. J Clin Oncol 2007 25 2198-2204 (Pubitemid 46954643)
37. Twelves C, Wong A, Nowacki M P. et al. Capecitabine as adjuvant treatment for stageIII colon cancer. N Engl J Med 2005 352 2696-2704 (Pubitemid 41007824)
38. Haller D, Tabernero J, Maroun J et al. First efficacy findings from a randomized phaseIII trial of capecitabine+oxaliplatin vs. bolus 5-FU/LV for stageIII colon cancer (NO16968/XELOXA study). Eur J Cancer 2009 4
39. Saltz L B., Niedzwiecki D, Hollis D et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stageIII colon cancer: results of CALGB 89803. JClin Oncol 2007 25 3456-3461 (Pubitemid 47310883)
40. Van Cutsem E, Labianca R, Bodoky G et al. Randomized phaseIII trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stageIII colon cancer: PETACC-3. J Clin Oncol 2009 27 3117-3125
41. Wolmark N, Yothers G, OConnell M J. et al. A phaseIII trial comparing mFOLFOX6 to mFOLFOX6 plus bevacizumab in stageII or III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol 2009 18
42. Alberts S R., Sargent D J., Smyrk T C. et al. Adjuvant mFOLFOX6 with or without cetuximab (Cmab) in KRAS wild-type (WT) patients (pts) with resected stageIII colon cancer (CC): results from NCCTG Intergroup phaseIII trial N0147. J Clin Oncol 2010 28 18
43. Chau I, Cunningham D. Adjuvant therapy in colon cancer: what, when and how? Ann Oncol 2006 1 1347-1359 (Pubitemid 44400373)
44. Jackson McCleary A J., Meyerhardt J, Green E et al. Impact of older age on the efficacy of newer adjuvant therapies in>12500patients with stageII/IIIcolon cancer: Findings from the ACCENT Database. J Clin Oncol 2009 27 15
45. Sargent D J., Goldberg R M., Jacobson S D. et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. NEngl J Med 2001 345 1091-1097
46. Schmiegel W, Pox C, Arnold D et al. Kolorektales Karzinom Polypenmanagement, (neo)adjuvante Therapie, Therapie im metastasierten Stadium. Dtsch Arztebl Int 2009 106 843-848
47. Link K H., Pillasch J, Formentini A et al. Downstaging by regional chemotherapy of non-resectable isolated colorectal liver metastases. Eur J Surg Oncol 1999 25 381-388 (Pubitemid 29364224)
48. Bismuth H, Adam R, Levi F et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996 224 509-522 (Pubitemid 26337559)
49. Simmonds P C., Primrose J N., Colquitt J L. et al. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer 2006 94 982-999
50. Nordlinger B, Sorbye H, Glemelius B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial. Lancet 2008 371 1007-1016 (Pubitemid 351392040)
51. Portier G, Dominique E, Bouche O et al. Multicenter randomized trial of adjuvant fluorouracil and folonic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006 24 4976-4982 (Pubitemid 46631399)
52. Langer B, Bleiberg H, Labianca R et al. Fluorouracil (FU) plus I-leucovorin (ILV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. Proc Am Soc Clin Oncol 2002 21
53. Mitry E, Fields A, Bleiberg H et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J Clin Oncol 2008 26 4906-4911
54. Ychou M, Hohenberger W, Thezenas S et al. Randomized phaseIII trial comparing infused 5-fluorouracil/folonic acid (LV5FU2) versus LV5FU2+irinotecan (LV5FU2+IRI) as adjuvant treatment after complete resection of liver metastases from colorectal cancer (LMCRC) (CPT-GMA-301). J Clin Oncol 2008 26 181
55. Alberts S R., Horvath W L., Sternfeld W C. et al. Oxaliplatin, fluorouracil and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: A North Central Cancer Treatment Group PhaseII Study. J Clin Oncol 2005 23 9243-9249
56. Pozzo C, Basso M, Cassano A et al. Neoadjuvant treatment of unresectable liver disease with irinotecan and 5-fluorouracil plus folinic acid in colorectal cancer patients. Ann Oncol 2004 15 933-939 (Pubitemid 39004350)
57. Folprecht G, Gruenberger T, Bechstein W O. et al. Tumor response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomized phase2 trial. Lancet Oncol 2010 11 38-47
58. Rubbia-Brandt L, Audard V, Sartoretti P et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 2004 15 460-466 (Pubitemid 38444550)
59. Pawlik T M., Olino K, Gleisner A L. et al. Preoperative chemotherapy for colorectal liver metastases: impact on hepatic histology and postoperative outcome. J Gastrointest Surg 2007 11 860-868
60. Vauthey J N., Pawlik T M., Ribero D et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 2006 24 2065-2072 (Pubitemid 46622116)
61. Mehta N N., Ravikumar R, Coldham C A. et al. Effect of preoperative chemotherapy on liver resection for colorectal liver metastases. Eur J Surg Oncol 2008 34 782-786
62. Dietmaier W. Mikrosatelliteninstabilität. Pathologe 2010 31 268-273
63. Koopman M, Kortman G A., Mekenkamp L et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 2009 100 266-273
64. Tejpar S, Bosman F, Delorenzi M et al. Micriosatellite instability (MSI) in stageII and III colon cancer treated with 5FU-LV or 5-FU-LV and irinotecan (PETACC 3 EORTC 40993 SAKK 60/00 trial). J Clin Oncol 2009 27 4001
65. Bertagnolli M M., Niedzwiecki D, Compton C C. et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil and leucovorin in stageIII colon cancer: Cancer and leukemia groupB protocol 89803. J Clin Oncol 2009 27 1814-1821
66. Kim S T., Lee J, Park S H. et al. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol 2010 66 659-667
67. Bekaii-Saab T. KRAS testing in metastatic colorectal cancer: Implications on the use of biologic agents. Clin Colorectal Cancer 2009; 8: 135140